A team from MIT's CSAIL launched Boltz as a public benefit corporation and closed a $28 million seed round to commercialize open AI models for molecular structure prediction and therapeutic design. The founders—researchers behind high‑accuracy structural models—position Boltz to deliver platform tools (Boltz Lab) enabling scientists to predict binding affinities and design candidate molecules without building proprietary discovery stacks. Investors including Amplify, a16z and Zetta backed the company; Boltz emphasizes an open‑science orientation and broad distribution to academic and industry researchers. The company previewed agents for small‑molecule discovery and protein design and said it will focus on infrastructure rather than building a traditional single‑asset therapeutics company.